Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX)

Conditions

previously untreated metastatic or locally advanced esophagogastric cancer

Brief summary

Progression free survival 1 and neurotoxicity. Progression free survival 1 is defined as the time from start of study treatment, until the first moment of disease progression.

Detailed description

Progression free survival 2: in case of reintroduction of study treatment after progression, progression free survival 2 is the time until progression occurs after this reintroduction. In case of start of second line treatment after progression, the time from start until discontinuation of second line is taken as progression free survival 2., Quality of life, Overall survival, Response rate according to RECIST 1.1, Adverse events according to NCI CTCAE version 5.0., Percentage of patients proceeding to subsequent lines of treatment after progression and describe the types of subsequent treatments, Reasons for forgoing subsequent treatment after progression, To compare the primary and above mentioned secondary objectives for patients treated with and without nivolumab

Denice Kamp, Merel van Velzen, Rob Kessels, Sebastiaan Siegerink, May Am et al. (12 authors)

Journal of Clinical Oncology2026-01-10

10.1200/jco.2026.44.2_suppl.lba287

Interventions

DRUGFluorouracil 50mg/ml Injection.

DRUGCarboplatin 10 mg/ml Intravenous Infusion

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUGOnivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion

DRUGXeloda 500 mg film-coated tablets

DRUGOxaliplatin 5mg/ml concentrate for Solution for Infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression free survival 1 and neurotoxicity. Progression free survival 1 is defined as the time from start of study treatment, until the first moment of disease progression.	—

Secondary

Measure	Time frame
Progression free survival 2: in case of reintroduction of study treatment after progression, progression free survival 2 is the time until progression occurs after this reintroduction. In case of start of second line treatment after progression, the time from start until discontinuation of second line is taken as progression free survival 2., Quality of life, Overall survival, Response rate according to RECIST 1.1, Adverse events according to NCI CTCAE version 5.0., Percentage of patients proceeding to subsequent lines of treatment after progression and describe the types of subsequent treatments, Reasons for forgoing subsequent treatment after progression, To compare the primary and above mentioned secondary objectives for patients treated with and without nivolumab	—

Measure

Time frame

Progression free survival 2: in case of reintroduction of study treatment after progression, progression free survival 2 is the time until progression occurs after this reintroduction. In case of start of second line treatment after progression, the time from start until discontinuation of second line is taken as progression free survival 2., Quality of life, Overall survival, Response rate according to RECIST 1.1, Adverse events according to NCI CTCAE version 5.0., Percentage of patients proceeding to subsequent lines of treatment after progression and describe the types of subsequent treatments, Reasons for forgoing subsequent treatment after progression, To compare the primary and above mentioned secondary objectives for patients treated with and without nivolumab

—

Countries

Netherlands

Outcome results

None listed